Abstract:Background: Previous studies reported on the existence of atrophy-based Alzheimer's disease (AD) subtypes that associate with distinct clinical symptoms. However, the consistency of AD atrophy subtypes across approaches remains uncertain. This large-scale study aims to assess subtype concordance in individuals using two methods of data-driven subtyping. Methods: We included n=10,011 patients across the clinical spectrum from 10 AD cohorts across Europe, United States, and Australia, and extracted regional volumes using Freesurfer v7.1.1. To characterise atrophy heterogeneity in the AD continuum, we introduced a hybrid two-step approach called Snowphlake (Staging NeurOdegeneration With PHenotype informed progression timeLine of biomarKErs) to identify subtypes and sequence of atrophy-events within each subtype. We compared our results with SuStaIn (Subtype and Stage Inference) which jointly estimates both, and was trained and validated similarly. The training dataset included Aβ+ participants (n=1,195), and a control group of Aβ- cognitively unimpaired participants (n=1,692). We validated model staging within each subtype, in a held-out clinical-validation dataset (n=6,362) comprising patients across the clinical spectrum irrespective of Aβ biomarker status and an independent external dataset (n=762). Furthermore, we validated the clinical significance of the detected subtypes, in a subset of Aβ+ validation datasets with n=1,796 in the held-out sample and n=159 in the external dataset. Lastly, we performed concordance analysis to assess the consistency between the methods. Results: In the AD dementia (AD-D) training data, Snowphlake identified four subtypes: diffuse cortical atrophy (21.1%,age 67.5±9.3), parieto-temporal atrophy (19.8%,age 60.9±7.9), frontal atrophy (24.8%,age 67.6±8.8) and subcortical atrophy (25.1%,68.3±8.2). The subtypes assigned in Aβ+ validation datasets were associated with alterations in specific cognitive domains (Cohen's f: [0.15-0.33]), while staging correlated with Mini-Mental State Examination (MMSE) scores (R: [-0.51 to -0.28]) in the validation datasets. SuStaIn also identified four subtypes: typical (55.7%,age 66.7±7.8), limbic-predominant (24.2%,age 72.2±6.6), hippocampal-sparing (14.6%,age 62.8±6.9), and subcortical (0.8%,age 68.2±7.6). The subtypes assigned in Aβ+ validation datasets using SuStaIn were also associated with alterations in specific cognitive domains (Cohen's f:[0.17-0.34]), while staging correlated with MMSE scores in the validation datasets (R: [-0.54 to -0.26]). However, we observed low concordance between Snowphlake and SuStaIn, with 39.7% of AD-D patients consistently grouped in concordant subtypes by both the methods. Conclusion: In this multi-cohort study, both Snowphlake and SuStaIn identified four subtypes that were associated with different symptom profiles and atrophy-severity measures that were associated with global cognition. The low concordance between Snowphlake and SuStaIn suggests that heterogeneity may rather be a spectrum than discretised by subtypes.

Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson's disease

Two Distinct Trajectories of Clinical and Neurodegeneration Events in Parkinson’s Disease

Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease

Identification of Parkinson's disease subtypes with distinct brain atrophy progression and its association with clinical progression

Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression

Spatiotemporal Neurodegeneration of the Substantia Nigra and Its Connecting Cortex and Subcortex in Parkinson's Disease.

Distinct Longitudinal Clinical-Neuroanatomical Trajectories in Parkinson's Disease Clinical Subtypes: Insight Towards Precision Medicine

MRI subtypes in Parkinson's disease across diverse populations and clustering approaches

Identification of Parkinson’s Disease PACE Subtypes and Repurposing Treatments Through Integrative Analyses of Multimodal Data

Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder

Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer’s Disease

Connectivity-Based Subtyping of De Novo Parkinson Disease: Biomarkers, Medication Effects and Longitudinal Progression

The Longitudinal Volumetric and Shape Changes of Subcortical Nuclei in Parkinson’s Disease

A reliable subtyping of de novo Parkinson disease: biomarkers, medication effects and longitudinal progression

Association of Specific Biotypes in Patients with Parkinson Disease and Disease Progression

A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings

Distinct spatiotemporal patterns of cortical thinning in Alzheimer's disease-type cognitive impairment and subcortical vascular cognitive impairment

A large-scale multi-centre study characterising atrophy heterogeneity in Alzheimer's disease

Disease Progression of Data-Driven Subtypes of Parkinson's Disease: 5-Year Longitudinal Study from the Early Parkinson's disease Longitudinal Singapore (PALS) Cohort

Spatial-temporal dynamic evolution of lewy body dementia by metabolic PET imaging

Morphologic changes in the mesolimbic pathway in Parkinson's disease motor subtypes